NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

Actinium Pharmaceuticals, Inc. (ATNM) Stock Analysis

Actinium Pharmaceuticals, Inc. (ATNM) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

ATNM

$1.38

−$0.02 (−1.43%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATNM with… →

ATNM Key Statistics

As of Oct 21, 2026
Trading
Open
$1.38
Previous Close
$1.40
Day's Range
1.33–1.41
52-Week Range
0.74–1.74
Volume
357.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.27
Valuation
Market Cap
$43.39M
P/E Ratio
3.83
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.24
EPS (ttm)Profit attributable to each share over the last twelve months.
0.36
Financials (FY)
Revenue (FY)
$90.00K
Net Income (FY)
−$33.89M
Profit marginThe share of revenue left as profit after all costs and taxes.
32.23%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
31.44M
1-Year Return
−8.61%
Dividend and dates
Avg Volume
165.74K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ATNM closed at $1.38, −8.61% over 1 year.

Actinium Pharmaceuticals, Inc. (ATNM) has a market capitalization of $43.39M.

In fiscal 2025, ATNM reported revenue of $90.00K.

ATNM Stock Return by Calendar Year

Actinium Pharmaceuticals, Inc. (ATNM) 10-year return: what $10,000 became

1 year
$10,000 $9,139
−8.61%
5 years
$10,000 $1,753
−82.47%
10 years
$10,000 $434
−95.66%

If you had invested $10,000 in Actinium Pharmaceuticals, Inc. (ATNM) 10 years ago, at the close on October 21, 2016, it would have been worth $434 at the close on October 21, 2026: −95.66% in total, −26.93% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.47%
2025+7.94%
2024−75.20%
2023−52.30%
2022+77.20%
2021−22.95%
2020+19.27%
2019−43.67%
2018−41.72%
2017−24.11%
2016 (partial year)−47.92%

As of October 21, 2026.

ATNM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$90.00K−$33.89M−37,652.2%
2024$0.00−$38.24M—
2023$81.00K−$48.82M−60,269.1%
2022$1.03M−$33.02M−3,205.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$90.00K—−$36.25M−$33.89M−37,652.2%
2024$0.00—−$42.12M−$38.24M—
2023$81.00K—−$51.92M−$48.82M−60,269.1%
2022$1.03M—−$34.10M−$33.02M−3,205.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATNM Valuation vs Biotechnology Median

Median of 608 stocks
MetricATNMBiotechnology medianvs median
P/E3.8316.600.2x the median
P/S ratio1.2413.300.1x the median
Profit margin32.23%−38.31%70.5 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Actinium Pharmaceuticals, Inc. (ATNM) is capitalised at $43.39M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 27.

Over the past 52 weeks the price has ranged from $0.74 to $1.74. The most recent close on file for ATNM is $1.38, dated October 21, 2026. That is −$0.02 (−1.43%) against the previous close. The latest close sits 87.76% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $90.00K. The same year closed with a net loss of $33.89M. The reported profit margin is 32.23%. That is 70.5 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 0.36.

Across the 4 fiscal years on file, revenue moves from $1.03M in 2022 to $90.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 3.83 times earnings. That is 0.2 times the Biotechnology median of 16.6. The price-to-sales ratio is 1.24. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −8.61%. Measured over 10 years, that is −26.93% a year compounded. The reported beta is 0.27. Annualized volatility over the trailing 10 years is 81.94%.

Growth & Income

The record shows no dividend for ATNM.

Across the complete calendar years on file, 2022 returned +77.20% and 2024 returned −75.20%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is +1.47% year to date.

Peer Comparison

Actinium Pharmaceuticals, Inc. (ATNM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Actinium Pharmaceuticals, Inc. ATNM $43.39M 3.8
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Actinium Pharmaceuticals, Inc. trades at a P/E of 3.8.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Visit website →